Pilot Study of Posaconazole in Crohn's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04966585|
Recruitment Status : Recruiting
First Posted : July 19, 2021
Last Update Posted : May 24, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Crohn Disease CARD9 S12N Risk Allele||Drug: Posaconazole Delayed Release Oral Tablet Drug: Matching Placebo Tablet||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Subjects will be randomly assigned to receive posaconazole or placebo in 1:1 fashion.|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Masking Description:||Both subject and clinical staff will be masked to treatment group assigned.|
|Official Title:||A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease|
|Actual Study Start Date :||August 17, 2022|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||December 31, 2024|
Subjects administered posaconazole (Noxifil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
Drug: Posaconazole Delayed Release Oral Tablet
Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Other Name: Noxifil
Placebo Comparator: Placebo
Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
Drug: Matching Placebo Tablet
Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
- Endoscopic Response [ Time Frame: Week 12 ]Defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease.
- Induction of Clinical Remission [ Time Frame: Week 12 ]
Defined as Patient-Reported Outcome (PRO2) abdominal pain score ≤1 AND stool frequency ≤3, and Crohn's Disease Activity Index (CDAI) (<150).
PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity.
- Incidence of adverse events [ Time Frame: Week 12 ]
- Change in amount of concomitant medications [ Time Frame: Week 12 ]
- Proportion of subjects in endoscopic remission [ Time Frame: Week 12 ]Defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≤3. The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 56, with higher scores indicating more severe disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 60 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female patients aged 18 to 60 years, inclusive based on the date of the screening visit.
- A diagnosis of CD with minimum disease duration of 6 months with involvement of the ileum and/or colon documented on colonoscopy
- Have an endoscopically-confirmed active Crohn's disease with active disease defined by SES-CD > 6 (>4 if ileal only), AND active symptoms of Crohn's disease (CDAI score >220)
- Homozygous for CARD9 SN12 risk allele, without the protective exon 11 polymorphism
- Subjects receiving oral aminosalicylates (at a stable dose for 2 weeks prior to baseline), immunomodulators (at a stable dose for 4 weeks prior to baseline), anti-TNF, anti IL12/23, or anti-integrin therapy (at stable maintenance doses for > 8 weeks) may continue their use during the study.
- Subjects receiving oral corticosteroids may continue their use during the study provided the dose (prednisone up to 20 mg/day, budesonide up to 9 mg/day) has been stable for two weeks prior to screening.
- Have had age-appropriate and disease-duration-appropriate colon cancer screening1 without unresected dysplasia.
- Women of childbearing age, excluding those with prior bilateral tubal ligation or at least one-year post-menopause, must not be pregnant, lactating, or planning to become pregnant. They must agree to use effective contraception throughout the study period.
- Subjects must be able to provide informed consent and understand, agree with, and be able to adhere to daily diary entries, all scheduled visits, tests, procedures, and protocol in English.
- Known hypersensitivity or allergy to posaconazole or other azole antifungal agents
- Concomitant medications primarily metabolized by CY3PA4 including: a) HMG-CoA inhibitors primarily metabolized by CY3PA4 (increases risk of rhabdomyolysis), b) Sirolimus, c) Ergot alkaloids, d) vincristine
- Proarrhythmic conditions
- Moderate or severe renal impairment (Cr Clearance <50)
- Current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, infectious colitis, or microscopic colitis.
- Fulminant colitis, toxic megacolon, peritonitis, ileostomy or colostomy.
- Stool sample positive for pathogens including ova and parasites, Salmonella, Shigella, and C. difficile at screening.
- History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease or any other medical condition that, in the Investigators opinion, would prevent the subject from participation in the study.
- Treatment with antibiotics, antifungal agents, probiotics, or prebiotics within two weeks of screening.
- Alcohol or drug abuse (in the opinion of the Investigator) that would interfere with compliance.
- Any other investigational therapy or treatment within four weeks of screening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04966585
|Contact: Melissa Hamptonfirstname.lastname@example.org|
|United States, California|
|Cedars-Sinai Medical Center (CSMC)||Recruiting|
|Los Angeles, California, United States, 90048|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55901|
|Principal Investigator:||Gil Y Melmed, MD||Cedars-Sinai Medical Center|
|Responsible Party:||Gil Melmed, Principal Investigator, Cedars-Sinai Medical Center|
|Other Study ID Numbers:||
1R01DK125495-01A1 ( U.S. NIH Grant/Contract )
|First Posted:||July 19, 2021 Key Record Dates|
|Last Update Posted:||May 24, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Inflammatory Bowel Diseases
Digestive System Diseases
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs